The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China

David S. Hui

PII: S1201-9712(20)30011-4
DOI: https://doi.org/10.1016/j.ijid.2020.01.009
Reference: IJID 3900
To appear in: International Journal of Infectious Diseases

Esam El Azhar

PII: S1201-9712(20)30011-4
DOI: https://doi.org/10.1016/j.ijid.2020.01.009
Reference: IJID 3900
To appear in: International Journal of Infectious Diseases

Tariq A. Madani

PII: S1201-9712(20)30011-4
DOI: https://doi.org/10.1016/j.ijid.2020.01.009
Reference: IJID 3900
To appear in: International Journal of Infectious Diseases

Francine Ntoumi
Title: The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China

Authors: David S Hui\textsuperscript{1}, Esam El Azhar\textsuperscript{3}, Tariq A Madani\textsuperscript{4}, Francine Ntoumi\textsuperscript{5}, Richard Kock\textsuperscript{6}, Osman Dar\textsuperscript{7}, Giuseppe Ippolito\textsuperscript{8}, Timothy D Mchugh\textsuperscript{9}, Ziad A Memish\textsuperscript{10}, Christian Drosten\textsuperscript{11}, Alimuddin Zumla\textsuperscript{12} and Eskild Petersen\textsuperscript{13}

Institutional Affiliations:

\textbullet{} \textsuperscript{1}Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China. Electronic address: dschui@cuhk.edu.hk.

\textbullet{} \textsuperscript{3}Special Infectious Agents Unit, King Fahd Medical Research Center and; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: eazhar@kau.edu.sa

\textbullet{} \textsuperscript{4}Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: taamadani@yahoo.com

\textbullet{} \textsuperscript{5}Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of Congo. Electronic address: fntoumi@fcrm-congo.com

\textbullet{} \textsuperscript{6}The Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hatfield, Hertfordshire. Email: rkock@rvc.ac.uk

\textbullet{} \textsuperscript{7}Chatham House Centre on Global Health Security, Royal Institute of International Affairs, London, UK. Electronic address: Osman.Dar@phe.gov.uk.

\textbullet{} \textsuperscript{8}Lazzaro Spallanzani, National Institute for Infectious Diseases - IRCCS, Rome, Italy. Electronic address: giuseppe.ippolito@inmi.it.

\textbullet{} \textsuperscript{9}Center for Clinical Microbiology, Division of Infection and Immunity, University College London, United Kingdom. Electronic email: t.mchugh@ucl.ac.uk

\textbullet{} \textsuperscript{10}College of Medicine, Alfaisal University, Riyadh, Saudi Arabia; Infectious Diseases Division, Department of Medicine, Prince Mohamed Bin Abdulaziz Hospital, Ministry of Health, Riyadh, Saudi Arabia. Electronic address: zmemish@yahoo.com.
The city of Wuhan in China is the focus of global attention due to an outbreak of a febrile respiratory illness due to a novel coronavirus. In December 2019, there was an outbreak of pneumonia of unknown cause in Wuhan, Hubei province in China, with an epidemiological link to the Huanan Seafood Wholesale Market where there was also sale of live animals. Notification of the WHO on 31 Dec 2019 by the Chinese Health Authorities has prompted health authorities in Hong Kong, Macau, and Taiwan to step up border surveillance, and generated concern and fears that it could mark the emergence of a novel and serious threat to public health.\textsuperscript{1,2} The Chinese health authorities have taken prompt public health measures including intensive surveillance, epidemiological investigations, and closure of the market on 1 Jan 2020. SARS-CoV, MERS-CoV, avian influenza, influenza and other common respiratory viruses were ruled out. The Chinese scientists were able to isolate a novel CoV from a patient within a short time on 7 Jan 2020 and perform genome sequencing of the novel CoV. The genetic sequence of the novel CoV has become available to the WHO on 12 Jan 2020 and this has facilitated the laboratories in different countries to produce specific diagnostic PCR tests for detecting the
The novel CoV is a β CoV of group 2B with at least 70% similarity in genetic sequence to SARS-CoV.

SARS is a zoonosis caused by SARS-CoV, which first emerged in China in 2002 before spreading to 29 countries/regions in 2003 through a travel-related global outbreak with 8,098 cases with a case fatality rate of 9.6%. Nosocomial transmission of SARS-CoV was common while the primary reservoir was bats and the intermediary source was civet cats in the wet markets in Guangdong. MERS is a novel lethal zoonotic disease of humans endemic to the Middle East, caused by MERS-CoV. Humans are thought to acquire MERS-CoV infection through contact with camels or camel products with a case fatality rate close to 35% while nosocomial transmission is also a hallmark. The recent outbreak of clusters of viral pneumonia due to a novel CoV in the Wuhan market poses significant threats to international health and may be related to sale of wild animal as game food at the seafood market.

As of 10 Jan 2020, 41 patients have been diagnosed to have infection by the novel CoV. The onset of illness of the 41 cases ranges from 8 December 2019 to 2 January 2020. Symptoms include fever (>90% cases), malaise, dry cough (80%), shortness of breath (20%) and respiratory distress (15%). The vital signs were stable in most of the cases while leucopenia and lymphopenia were common. Among the 41 cases, six patients have been discharged, seven patients are in critical care and one died, while the remaining patients are in stable condition. The fatal case involved a 61 year-old man with an abdominal tumour and cirrhosis who was admitted to a hospital due to respiratory failure and severe pneumonia. The diagnoses included severe pneumonia, acute respiratory distress syndrome, septic shock and multi-organ failure. The novel CoV infection in Wuhan appears clinically milder than SARS or MERS overall in terms of severity, case fatality rate and transmissibility. There is currently no clear evidence of human to human transmission. At present, 739 close contacts including 419 healthcare workers are being quarantined and monitored for any development of symptoms. No new cases have been detected in Wuhan since 3 January 2020. However the first case outside China has been reported today, 13th January 2020 in a Chinese tourist visiting Thailand, who is being treated in hospital.

The Chinese Health Authorities have carried out very appropriate and prompt response measures including active case finding, and retrospective investigations of the current cluster of patients which have been completed; The Huanan Seafood Wholesale Market has been
temporarily closed to carry out investigation, environmental sanitation and disinfection; Public risk communication activities have been carried out to improve public awareness and adoption of self-protection measures. Technical guidance on novel coronavirus has been developed and will continue to be updated as additional information becomes available.

However, many questions about the new coronavirus remain. While it appears to be transmitted to humans via animals, the specific animals and other reservoirs need to be identified, the transmission route, the incubation period and characteristics of the susceptible population and survival rates. At present, there is however very limited clinical information of the novel CoV infection and data are missing in regard to the age range, animal source of the virus, incubation period, epidemic curve, viral kinetics, transmission route, pathogenesis, autopsy findings and any treatment response to antivirals among the severe cases. Once there is any clue to the source of animals being responsible for this outbreak, global public health authorities should examine the trading route and source of movement of wild animals from other parts to Wuhan and prevent further such trade which is posing risk to human health. The rapid identification and containment of a novel coronavirus virus rapidly in a short period of time (phylogenetic tree Archive Number: 20200112.6885385) is a re-assuring and a commendable achievement by China’s public health authorities and reflects the increasing global capacity to detect, identify, define and contain new outbreaks.

This outbreak brings back memories of of the novel coronavirus outbreak in China, the severe acute respiratory syndrome (SARS) in China in 2003, caused by a novel SARS-CoV-coronavirus.\textsuperscript{7} SARS-CoV rapidly spread from southern China in 2003 and infected more than 3,000 people, killing 774 by 2004, and then disappeared - never to be seen again.

However, The Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV)\textsuperscript{8}, a lethal zoonotic pathogen that was first identified in humans in the Kingdom of Saudi Arabia (KSA) in 2012 continues to show up through intermittent sporadic cases, community clusters and nosocomial outbreaks. Between 2012 and December 2019, a total of 2465 laboratory-confirmed cases of MERS-CoV infection, including 850 deaths (34.4% mortality) were reported from 27 countries to WHO, the majority of which were reported by KSA (2073 cases, 772 deaths. Whilst several important aspects of MERS-CoV epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, have been defined, there remain many unanswered questions, including source, transmission and epidemic potential. The Wuhang outbreak is a stark reminder of the continuing threat of zoonotic diseases to global health security. More
funder and governmental investments are required for a more concerted and collaborative global effort, learning from experiences from all geographical regions, through a ‘ONE-HUMAN-ENVIRONMENTAL-ANIMAL-HEALTH’ global consortium to reduce the global threat of zoonotic diseases.\(^9\)

**Author declarations:**

All authors have a specialist interest in emerging and re-emerging pathogens. FN, OD, GI, CD are members of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET) funded by the European and Developing Countries Clinical Trials Partnership the EU Horizon 2020 Framework Programme for Research and Innovation. AZ has received a National Institutes of Health Research senior investigator award.

**Author declarations:**

All authors have a specialist interest in emerging and re-emerging pathogens. FN, OD, GI, CD are members of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET) funded by the European and Developing Countries Clinical Trials Partnership the EU Horizon 2020 Framework Programme for Research and Innovation. AZ has received a National Institutes of Health Research senior investigator award. All authors declare no conflicts of interest.
References


2. Parr J. Pneumonia in China: lack of information raises concerns among Hong Kong health workers. BMJ 2020;368:m56 doi: 10.1136/bmj.m56 (Published 8 January 2020)


